Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Peter C. Enzinger, M.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Bendell JC, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Lockhart AC, Knutson KL, Yen J, Franovic A, Nordstrom JL, Li D, Wigginton J, Davidson-Moncada JK, Rosales MK, Bang YJ. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial. Lancet Oncol. 2020 Jul 09. PMID: 32653053.
    Citations:    
  2. Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PA, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ, Zhang C, Kaur N, Elmonshed D, Galletti G, Sarkar S, Bhinder B, Pittman ME, Plotnikova OM, Kotlov N, Frenkel FE, Bagaev AV, Elemento O, Betel D, Giannakakou P, Lenz HJ. Multicenter phase II study of Cabazitaxel in advanced gastroesophageal cancer: Association of HER2 Expression and M2-like Tumor Associated Macrophages with Patient Outcome. Clin Cancer Res. 2020 Jul 08. PMID: 32641434.
    Citations:    
  3. Wang X, Zhao J, Shen Z, Fairweather M, Enzinger PC, Sun Y, Wang J. Multidisciplinary Approach in Improving Survival Outcome of Early-Stage Gastric Cancer. J Surg Res. 2020 Jun 20; 255:285-296. PMID: 32574755.
    Citations:    
  4. Catenacci DVT, Rasco D, Lee J, Rha SY, Lee KW, Bang YJ, Bendell J, Enzinger P, Marina N, Xiang H, Deng W, Powers J, Wainberg ZA. Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. J Clin Oncol. 2020 Jul 20; 38(21):2418-2426. PMID: 32167861.
    Citations:    
  5. Kato K, Shah M, Enzinger P, Bennouna J, Shen L, Adenis A, Sun J, Cho B, Ozguroglu M, Kojima T, Kostorov V, Hierro C, Zhu Y, Shah S, Bhagia P, Doi T. A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 - Trial in progress. Ann Oncol. 2018 Jun; 29 Suppl 5:v14-v15. PMID: 32177025.
    Citations:    
  6. Goyal L, Chaudhary SP, Kwak EL, Abrams TA, Carpenter AN, Wolpin BM, Wadlow RC, Allen JN, Heist R, McCleary NJ, Chan JA, Goessling W, Schrag D, Ng K, Enzinger PC, Ryan DP, Clark JW. A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer. Invest New Drugs. 2020 Jan 02. PMID: 31898183.
    Citations:    
  7. Metges J, François E, Shah M, Adenis A, Enzinger P, Kojima T, Muro K, Bennouna J, Hsu C, Moriwaki T, Kim S, Lee S, Kato K, Shen L, Qin S, Ferreira P, Wang R, Bhagia P, Kang S, Doi T. The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. Ann Oncol. 2019 Jul; 30 Suppl 4:iv130. PMID: 32085031.
    Citations:    
  8. Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Leong S, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Paluri RK, Park H, Perry KA, Pimiento J, Poultsides GA, Roses R, Strong VE, Wiesner G, Willett CG, Wright CD, McMillian NR, Pluchino LA. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 07 01; 17(7):855-883. PMID: 31319389.
    Citations:    
  9. Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bhagia P, Kato K. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. JAMA Oncol. 2019 Apr 01; 5(4):546-550. PMID: 30570649.
    Citations:    Fields:    
  10. Cleary JM, Horick NK, McCleary NJ, Abrams TA, Yurgelun MB, Azzoli CG, Rubinson DA, Brooks GA, Chan JA, Blaszkowsky LS, Clark JW, Goyal L, Meyerhardt JA, Ng K, Schrag D, Savarese DMF, Graham C, Fitzpatrick B, Gibb KA, Boucher Y, Duda DG, Jain RK, Fuchs CS, Enzinger PC. FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial. Cancer. 2019 07 01; 125(13):2213-2221. PMID: 30913304.
    Citations:    
  11. Kato K, Shah MA, Enzinger P, Bennouna J, Shen L, Adenis A, Sun JM, Cho BC, Özgüroglu M, Kojima T, Kostorov V, Hierro C, Zhu Y, McLean LA, Shah S, Doi T. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019 Apr; 15(10):1057-1066. PMID: 30735435.
    Citations:    
  12. Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 03; 20(3):420-435. PMID: 30718072.
    Citations:    
  13. Cartwright E, Keane FK, Enzinger PC, Hong T, Chau I. Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma? Am Soc Clin Oncol Educ Book. 2018 May 23; 38:280-291. PMID: 30231360.
    Citations:    Fields:    Translation:Humans
  14. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 05 10; 4(5):e180013. PMID: 29543932.
    Citations: 18     Fields:    
  15. Gerbaudo VH, Killoran JH, Kim CK, Hornick JL, Nowak JA, Enzinger PC, Mamon HJ. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response. Ann Nucl Med. 2018 Apr; 32(3):165-174. PMID: 29332233.
    Citations:    Fields:    Translation:Humans
  16. Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10; 35(32):3671-3677. PMID: 28976791.
    Citations: 5     Fields:    Translation:Humans
  17. Sanford NN, Catalano PJ, Enzinger PC, King BL, Bueno R, Martin NE, Hong TS, Wo JY, Mamon HJ. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. Dis Esophagus. 2017 Jul 01; 30(7):1-8. PMID: 28475728.
    Citations: 3     Fields:    Translation:Humans
  18. Doi T, Bennouna J, Shen L, Enzinger P, Wang R, Dalal R, Koshiji M, Shah M. Pembrolizumab versus investigator's choice single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma that progressed after first-line therapy: Phase 3 KEYNOTE-181 study. Ann Oncol. 2017 Jun; 28 Suppl 3:iii33. PMID: 32135867.
    Citations:    
  19. Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang H, Fasanmade A, Danaee H, Kalebic T. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Invest New Drugs. 2017 10; 35(5):634-641. PMID: 28527133.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  20. Enzinger AC, Wind JK, Frank E, McCleary NJ, Porter L, Cushing H, Abbott C, Cronin C, Enzinger PC, Meropol NJ, Schrag D. A stakeholder-driven approach to improve the informed consent process for palliative chemotherapy. Patient Educ Couns. 2017 Aug; 100(8):1527-1536. PMID: 28359659.
    Citations: 2     Fields:    Translation:Humans
  21. Benson AB, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 03; 15(3):370-398. PMID: 28275037.
    Citations: 42     Fields:    Translation:Humans
  22. Mawardi H, Enzinger P, McCleary N, Manon R, Villa A, Treister N, Woo SB. Osteonecrosis of the jaw associated with ziv-aflibercept. J Gastrointest Oncol. 2016 Dec; 7(6):E81-E87. PMID: 28078129.
    Citations: 2     
  23. Cleary JM, Mamon HJ, Szymonifka J, Bueno R, Choi N, Donahue DM, Fidias PM, Gaissert HA, Jaklitsch MT, Kulke MH, Lynch TP, Mentzer SJ, Meyerhardt JA, Swanson RS, Wain J, Fuchs CS, Enzinger PC. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer. 2016 07 13; 16:468. PMID: 27412386.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  24. Enzinger PC, Burtness BA, Niedzwiecki D, Ye X, Douglas K, Ilson DH, Villaflor VM, Cohen SJ, Mayer RJ, Venook A, Benson AB, Goldberg RM. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol. 2016 08 10; 34(23):2736-42. PMID: 27382098.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  25. Mahadevan A, Dagoglu N, Mancias J, Raven K, Khwaja K, Tseng JF, Ng K, Enzinger P, Miksad R, Bullock A, Evenson A. Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. J Cancer. 2015; 6(11):1099-104. PMID: 26516357.
    Citations: 16     
  26. Spector R, Zheng Y, Yeap BY, Wee JO, Lebenthal A, Swanson SJ, Marchosky DE, Enzinger PC, Mamon HJ, Lerut A, Odze R, Srivastava A, Agoston AT, Tippayawang M, Bueno R. The 3-Hole Minimally Invasive Esophagectomy: A Safe Procedure Following Neoadjuvant Chemotherapy and Radiation. Semin Thorac Cardiovasc Surg. 2015; 27(2):205-15. PMID: 26686448.
    Citations: 3     Fields:    Translation:Humans
  27. Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D. Rectal Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13(6):719-28; quiz 728. PMID: 26085388.
    Citations: 33     Fields:    Translation:Humans
  28. Shah MA, Enzinger PC. Evidence-based management of advanced gastric cancer: current and emerging targeted therapies. Semin Oncol. 2014 Dec; 41(6):S1-2. PMID: 25499645.
    Citations:    
  29. Benson AB, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA. Colon cancer, version 3.2014. J Natl Compr Canc Netw. 2014 Jul; 12(7):1028-59. PMID: 24994923.
    Citations: 65     Fields:    Translation:Humans
  30. Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, Fuchs CS, McCleary NJ, Meyerhardt JA, Ng K, Schrag D, Sikora AL, Spicer BA, Killion L, Mamon H, Kimmelman AC. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014 Jun; 19(6):637-8. PMID: 24821822.
    Citations: 56     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  31. Brooks GA, Abrams TA, Meyerhardt JA, Enzinger PC, Sommer K, Dalby CK, Uno H, Jacobson JO, Fuchs CS, Schrag D. Identification of potentially avoidable hospitalizations in patients with GI cancer. J Clin Oncol. 2014 Feb 20; 32(6):496-503. PMID: 24419123.
    Citations: 18     Fields:    Translation:Humans
  32. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Localized colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 01; 11(5):519-28. PMID: 23667203.
    Citations: 29     Fields:    Translation:Humans
  33. Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS. Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist. 2013; 18(4):377-8. PMID: 23580238.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  34. Lee MS, Mamon HJ, Hong TS, Choi NC, Fidias PM, Kwak EL, Meyerhardt JA, Ryan DP, Bueno R, Donahue DM, Jaklitsch MT, Lanuti M, Rattner DW, Fuchs CS, Enzinger PC. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist. 2013; 18(3):281-7. PMID: 23429739.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  35. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Gregory KM, Freedman-Cass DA. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 Feb 01; 11(2):141-52; quiz 152. PMID: 23411381.
    Citations: 42     Fields:    Translation:Humans
  36. McCleary NJ, Wigler D, Berry D, Sato K, Abrams T, Chan J, Enzinger P, Ng K, Wolpin B, Schrag D, Fuchs CS, Hurria A, Meyerhardt JA. Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy. Oncologist. 2013; 18(1):64-72. PMID: 23287880.
    Citations: 13     Fields:    Translation:Humans
  37. Benson AB, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih MG, Fuchs CS, Grem JL, Hunt S, Leong LA, Lin E, Martin MG, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett CG, Freedman-Cass DA, Gregory KM. Rectal cancer. J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1528-64. PMID: 23221790.
    Citations: 42     Fields:    Translation:Humans
  38. Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012 Aug 20; 30(24):2963-8. PMID: 22778320.
    Citations: 53     Fields:    Translation:HumansCTClinical Trials
  39. Dulak AM, Schumacher SE, van Lieshout J, Imamura Y, Fox C, Shim B, Ramos AH, Saksena G, Baca SC, Baselga J, Tabernero J, Barretina J, Enzinger PC, Corso G, Roviello F, Lin L, Bandla S, Luketich JD, Pennathur A, Meyerson M, Ogino S, Shivdasani RA, Beer DG, Godfrey TE, Beroukhim R, Bass AJ. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 2012 Sep 01; 72(17):4383-93. PMID: 22751462.
    Citations: 89     Fields:    Translation:HumansCells
  40. Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012; 7(6):e38231. PMID: 22701615.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  41. Brooks GA, Enzinger PC, Fuchs CS. Adjuvant therapy for gastric cancer: revisiting the past to clarify the future. J Clin Oncol. 2012 Jul 01; 30(19):2297-9. PMID: 22585690.
    Citations: 8     Fields:    Translation:Humans
  42. Benson AB, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fakih MG, Fleshman JW, Fuchs CS, Grem JL, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett C, Freedman-Cass DA. Anal Carcinoma, Version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Apr; 10(4):449-54. PMID: 22491045.
    Citations: 17     Fields:    Translation:Humans
  43. Elnahal SM, Shinagare AB, Szymonifka J, Hong TS, Enzinger PC, Mamon HJ. Prevalence and significance of subcentimeter hepatic lesions in patients with localized pancreatic adenocarcinoma. Pract Radiat Oncol. 2012 Oct-Dec; 2(4):e89-e94. PMID: 24674191.
    Citations: 1     Fields:    
  44. Benson AB, Arnoletti JP, Bekaii-Saab T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF, Enzinger PC, Fleshman JW, Fuchs CS, Grem JL, Knol JA, Leong LA, Lin E, May KS, Mulcahy MF, Murphy K, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Small W, Sofocleous CT, Venook AP, Willett C. Colon cancer. J Natl Compr Canc Netw. 2011 Nov; 9(11):1238-90. PMID: 22056656.
    Citations: 12     Fields:    Translation:Humans
  45. Faris JE, Arnott J, Zheng H, Ryan DP, Abrams TA, Blaszkowsky LS, Clark JW, Enzinger PC, Hezel AF, Ng K, Wolpin BM, Kwak EL. A phase 2 study of oral MKC-1, an inhibitor of importin-ß, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug; 30(4):1614-20. PMID: 21800081.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  46. Fuchs CS, Tepper JE, Niedzwiecki D, Hollis D, Mamon HJ, Swanson R, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Enzinger PC, Goldberg RM, Venook AP, Mayer RJ. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol. 2011 May 20; 29(15_suppl):4003. PMID: 28020574.
    Citations:    
  47. Smyth EC, Enzinger PC, Li J, Vincitore M, Lacy J, El-Rayes BF, Kunz PL, Ford JM, Robinson E, Kelsen DP, Shah MA. Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience. J Clin Oncol. 2011 May 20; 29(15_suppl):4056. PMID: 28020511.
    Citations:    
  48. Schoenfeld JD, Mamon HJ, Blaszkowsky LS, Enzinger PC, Wo JY, Allen JN, Wadlow RC, Ryan DP, Hong TS. Gastric adenocarcinoma treated with radiation with or without epirubicin-based chemotherapy: Evaluation of radiation-induced liver disease. J Clin Oncol. 2011 Feb; 29(4_suppl):110. PMID: 27985444.
    Citations:    
  49. Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, Wolpin BM, Fidias P, Zheng H, Florio S, Regan E, Fuchs CS. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011 Jun; 22(6):1367-73. PMID: 21217058.
    Citations: 31     Fields:    Translation:HumansCTClinical Trials
  50. Engstrom PF, Arnoletti JP, Benson AB, Berlin JD, Berry JM, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E, Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM, Small W, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw. 2010 Jan; 8(1):106-20. PMID: 20064293.
    Citations: 18     Fields:    Translation:Humans
  51. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010 Jan; 11(1):48-54. PMID: 19932054.
    Citations: 66     Fields:    Translation:HumansCTClinical Trials
  52. Kulke MH, Tempero MA, Niedzwiecki D, Hollis DR, Kindler HL, Cusnir M, Enzinger PC, Gorsch SM, Goldberg RM, Mayer RJ. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. J Clin Oncol. 2009 Nov 20; 27(33):5506-12. PMID: 19858396.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  53. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):838-81. PMID: 19755047.
    Citations: 110     Fields:    Translation:Humans
  54. Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):778-831. PMID: 19755046.
    Citations: 131     Fields:    Translation:Humans
  55. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3027-35. PMID: 19470923.
    Citations: 169     Fields:    Translation:HumansCells
  56. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Muzikansky A, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Sahani DV. Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) in combination with gemcitabine (GEM) and oxaliplatin (OX). J Clin Oncol. 2009 May 20; 27(15_suppl):4578. PMID: 27963071.
    Citations:    
  57. Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Earle CC, Kulke MH, Meyerhardt JA, Blaszkowsky LS, Zhu AX, Fidias P, Vincitore MM, Mayer RJ, Fuchs CS. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol. 2009 Mar; 20(3):475-80. PMID: 19139178.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  58. Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009 Jan 01; 15(1):338-45. PMID: 19118063.
    Citations: 77     Fields:    Translation:Humans
  59. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009 Jan 10; 27(2):193-8. PMID: 19047305.
    Citations: 92     Fields:    Translation:HumansCellsCTClinical Trials
  60. Enzinger PC, Ryan DP, Regan EM, Lehman N, Abrams TA, Hezel AF, Fidias P, Sequist LV, Blaszkowsky LS, Fuchs CS. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):4552. PMID: 27949112.
    Citations:    
  61. Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007 Oct 20; 25(30):4787-92. PMID: 17947726.
    Citations: 40     Fields:    Translation:Humans
  62. Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007 Aug 01; 110(3):581-9. PMID: 17583545.
    Citations: 67     Fields:    Translation:HumansCTClinical Trials
  63. Meyerhardt JA, Stuart K, Fuchs CS, Zhu AX, Earle CC, Bhargava P, Blaszkowsky L, Enzinger P, Mayer RJ, Battu S, Lawrence C, Ryan DP. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol. 2007 Jul; 18(7):1185-9. PMID: 17483115.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  64. Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007 May; 450(5):529-37. PMID: 17372756.
    Citations: 53     Fields:    Translation:HumansCells
  65. Enzinger PC, Benedetti JK, Meyerhardt JA, McCoy S, Hundahl SA, Macdonald JS, Fuchs CS. Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg. 2007 Mar; 245(3):426-34. PMID: 17435550.
    Citations: 18     Fields:    Translation:Humans
  66. Meyerhardt JA, Clark JW, Supko JG, Eder JP, Ogino S, Stewart CF, D'Amato F, Dancey J, Enzinger PC, Zhu AX, Ryan DP, Earle CC, Mayer RJ, Michelini A, Kinsella K, Fuchs CS. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007 Oct; 60(5):661-70. PMID: 17216531.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  67. Meyerhardt JA, Stuart K, Fuchs CS, Zhu AX, Earle CC, Bhargava P, Blaszkowsky L, Enzinger PC, Mayer RJ, Battu S, Lawrence C, Ryan DP. . Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer. Annals of Oncology. 2007.
  68. Jackson NA, Enzinger PC. . GI Malignancies. Hazzard’s Principles of Geriatric Medicine and Gerontology. 2007.
  69. Ryan DP, Appleman LJ, Lynch T, Supko JG, Fidias P, Clark JW, Fishman M, Zhu AX, Enzinger PC, Kashala O, Cusack J, Eder JP. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer. 2006 Nov 15; 107(10):2482-9. PMID: 17036355.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  70. Wolpin BM, Clark JW, Meyerhardt JA, Earle CC, Ryan DP, Enzinger PC, Zhu AX, Blaszkowsky L, Battu S, Fuchs CS. Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Sep; 6(3):208-13. PMID: 17026790.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  71. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Aug 01; 24(22):3555-61. PMID: 16877721.
    Citations: 45     Fields:    Translation:HumansCTClinical Trials
  72. Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol. 2007 Feb; 59(3):285-93. PMID: 16786333.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  73. Zhu AX, Blaszkowsky L, Enzinger PC, Bhargava P, Ryan DP, Meyerhardt J, Horgan K, Hale K, Sheehan S, Stuart K. Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):14096. PMID: 27951886.
    Citations:    
  74. Enzinger PC, Yock T, Suh W, Fidias P, Mamon H, Choi N, Lehman N, Lawrence C, Lynch T, Fuchs C. Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4064. PMID: 27953592.
    Citations:    
  75. Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt J, Attawia M, Lawrence C, Fuchs CS. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4044. PMID: 27953648.
    Citations:    
  76. Kulke MH, Wu B, Ryan DP, Enzinger PC, Zhu AX, Clark JW, Earle CC, Michelini A, Fuchs CS. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006 Jun; 51(6):1033-8. PMID: 16865563.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  77. Kulke MH, Muzikansky A, Clark J, Enzinger PC, Fidias P, Kinsella K, Michelini A, Fuchs CS. A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. Cancer Invest. 2006 Jun-Jul; 24(4):346-50. PMID: 16777685.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  78. Meyerhardt JA, Heseltine D, Ogino S, Clark JW, Enzinger PC, Ryan DP, Earle CC, Zhu AX, Fuchs CS. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer. 2006 May; 6(1):59-65. PMID: 16796793.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  79. Meyerhardt JA, Zhu AX, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Earle CC, Vincitore M, Michelini A, Sheehan S, Fuchs CS. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol. 2006 Apr 20; 24(12):1892-7. PMID: 16622264.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  80. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Apr 20; 24(12):1898-903. PMID: 16622265.
    Citations: 101     Fields:    Translation:HumansCTClinical Trials
  81. Kulke MH, Wu B, Clark JW, Enzinger PC, Lynch TJ, Vincitore M, Michelini A, Fuchs CS. A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus. Cancer Invest. 2006 Apr-May; 24(3):229-34. PMID: 16809148.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  82. McCollum AD, Wu B, Clark JW, Kulke MH, Enzinger PC, Ryan DP, Earle CC, Michelini A, Fuchs CS. The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. Am J Clin Oncol. 2006 Feb; 29(1):40-4. PMID: 16462501.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  83. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006 Jan 20; 24(3):401-6. PMID: 16421420.
    Citations: 119     Fields:    Translation:HumansCTClinical Trials
  84. Enzinger PC, Yock T, Suh W, Fidias P, Mamon H, Choi N, Lehman C, Lawrence C, Lynch T, Fuchs C. . Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. Proc Annu Meet Am Soc Clin Oncol. 2006; 24:A4064.
  85. Zhu AX, Blaszkowsy L, Enzinger PC, Bhargava P, Ryan DP, Meyerhardt J, Horgan K, Hale K, Sheehan S, Stuart K. . Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. Proc Annu Meet Am Soc Clin Oncol. 2006; 24:A14096.
  86. Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A, Fuchs CS. . A phase II trial of irinotecan and cisplatin for advanced unresectable neuroendocrine tumors. Digestive Diseases and Sciences. 2006; 51(6):1033-38.
  87. Kulke MH, Stuart K, Earle CC, Bhargava P, Clark JW, Enzinger PC, Meyerhardt J, Attawia M, Lawrence C, Fuchs CS. . A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. Proc Annu Meet Am Soc Clin Oncol. 2006; 24(18S):A4044.
  88. Enzinger PC. . Colorectal cancer in the elderly. Muss HB, Hunter CP, Johnson KA, eds. Treatment and Management of Cancer in the Elderly. 2006; 265-85.
  89. Enzinger PC, Fidias P, Stuart K, Fuchs C, Bhargava P, Meyerhardt J, Earle C, Attawia M, Regan, E, Zhu AX. . Phase II study of bevacizumab and docetaxel (AVATAX) in metastatic esophageal and gastric cancer. Ann Oncol. 2006; 17(9):1078PD.
  90. Schernhammer ES, Enzinger PC. . Insulin-like growth factor receptor as a target for future therapeutic intervention. In Dittrich C, ed. Signal Transduction in Oncology. 2006; 101-118.
  91. Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec; 50(12):2218-23. PMID: 16416165.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  92. Meyerhardt JA, Heseltine D, Campos H, Holmes MD, Willett WC, Winer EP, Enzinger PC, Bunnell CA, Kulke MH, Fuchs CS. Assessment of a dietary questionnaire in cancer patients receiving cytotoxic chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8453-60. PMID: 16293876.
    Citations: 3     Fields:    Translation:Humans
  93. Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6650-6. PMID: 16166444.
    Citations: 55     Fields:    Translation:HumansCellsCTClinical Trials
  94. Clark JW, Zhu AX, Ryan DP, Meyerhardt J, Enzinger P, Earle C, Fuchs C, Anbe H, Houghton M, Kulke M. Phase I study of S-1 administrated for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer (AUGIC). J Clin Oncol. 2005 Jun; 23(16_suppl):4066. PMID: 27944174.
    Citations:    
  95. Zhu AX, Blaszkowsky L, Enzinger PC, Bhargava P, Ryan DP, Meyerhardt J, Horgan K, Hale K, Sheehan S, Stuart K. . Phase II study of cetuximab in patients with unresectable or metastatic hepatocellular carcinoma. Gastrointestinal ASCO Symposium. 2005; 197:183.
  96. Clark JW, Zhu AX, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Anbe M, Houghton M, Kulke M. . Phase I study of S-1 administrated for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer (AUGIC). Proc Annu Meet Am Soc Clin Oncol. 2005; 24:A4066.
  97. Enzinger PC. . Clinical trials in esophagogastric cancer. Cancer Invest. 2005; 24(A11).
  98. Enzinger PC, Fidias P, Meyerhardt J, Stuart K, Fuchs C, Huberman M, Goldstein M, Freter R, Attawia M, Lawrence C, Zhu AX. . Phase II study of bevacizumab and docetaxel (AvaTax) in metastatic esophageal and gastric cancer. Proc 2005 Gastrointestinal ASCO Symposium. 2005; 68:118.
  99. Enzinger PC, Earle C, Zhu A, Blaszkowsky L, Kulke M, Ryan D, Langford L, Michelini A, Meyerhardt J. . Phase I dose-finding and pharmacologic study of cisplatin (P), irinotecan (C), and either capecitabine (X) or infusional 5-FU (F) in patients (pts) with advanced gastrointestinal malignancies. Proc 2005 Gastrointestinal ASCO Symposium. 2005; 28:96.
  100. Enzinger PC, Fuchs CS. . Phase II Study of Docetaxel, Cisplatin, and Irinotecan (TPC) in Advanced Esophageal and Gastric Cancer. Ca Invest. 2005; 23(S1):30.
  101. Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A, Fuchs CS. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004 Sep 01; 101(5):934-9. PMID: 15329900.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  102. Enzinger PC, Clark J, Ryan D, Meyerhardt J, Kulke M, Fidias P, Earle C, Vincitore M, Michelini A, Fuchs C. Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4040. PMID: 28014372.
    Citations:    
  103. McCollum AD, Wu B, Clark J, Kulke M, Enzinger P, Ryan D, Earle C, Michelini A, Fuchs C. Capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3657. PMID: 28014585.
    Citations:    
  104. Meyerhardt JA, Xhu A, Enzinger PC, Ryan DP, Clark JW, Kulke MH, Michelini A, Vincitore M, Thomas A, Fuchs CS. Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3580. PMID: 28016332.
    Citations:    
  105. Enzinger PC. Colon cancer surgeries compared. In patients with certain characteristics, laparoscopically assisted colectomy works well. Health News. 2004 Jul; 10(7):3. PMID: 15239152.
    Citations:    Fields:    Translation:Humans
  106. Enzinger PC. Should people with Barrett's esophagus, who are at risk for cancer of the esophagus, avoid alcohol? Health News. 2004 Jun; 10(6):16. PMID: 15199910.
    Citations: 1     Fields:    Translation:Humans
  107. Enzinger PC, Mayer RJ. Gastrointestinal cancer in older patients. Semin Oncol. 2004 Apr; 31(2):206-19. PMID: 15112151.
    Citations: 4     Fields:    Translation:Humans
  108. Enzinger PC, Mamon H, Choi N, Bueno R, Kulke M, Fidias P, Donahue D, Mentzer S, Morgan J, Sugarbaker D, Liu G, Meyerhardt J, Wain J, Jaklitsch M, Lee J, Wright C, Michelini A, Ostler P, Langford L, Lynch T. . Phase II Cisplatin, Irinotecan, Celecoxib and Concurrent Radiation Therapy Followed by Surgery for Locally Advanced Esophageal Cancer. Proc Am Soc Clin Oncol Gastrointestinal Cancers Symposium. 2004; A35.
  109. Enzinger PC, Clark J, Ryan D, Meyerhardt J, Kulke P, Fidias P, Earle C, Vincitore M, Michelini A, Fuchs C. . Phase II study of docetaxel, cisplatin, and irinotecan in advanced esophageal and gastric cancer. Proc Annu Meet Am Soc Clin Oncol. 2004; 23:A4040.
  110. Enzinger PC, Earle C, Zhu A, Blaszkowsky L, Kulke M, Ryan D, Langford L, Michelini A, Meyerhardt J. . Phase I dose-finding and pharmacologic study of cisplatin (P), irinotecan (C), and either capecitabine (X) or infusional 5-FU (F) in patients (pts) with advanced solid tumors. Ann Oncol. 2004; 15(3):395P.
  111. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003 Dec 04; 349(23):2241-52. PMID: 14657432.
    Citations: 807     Fields:    Translation:Humans
  112. Enzinger PC, Mayer RJ. . Esophageal cancer (letter). N Engl J Med. 2003; 349(23):2241-52.
  113. Enzinger PC, Mamon H, Bueno R, Choi N, Fidias P, Kulke M, Sugarbaker D, Wright C, Donahue D, Lynch T. . Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. Proc Annu Meet Am Soc Clin Oncol. 2003; 22:A1451.
  114. Fuchs C, Fitzgerald H, Mamon H, Haller DG, Venook A, Enzinger P, Goldberg R, Gunderson L, Mayer R, Tepper J. . Postoperative adjuvant chemoradiation for gastric or gastroesophageal adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (RT): A multicenter pilot study. Proc Annu Meet Am Soc Clin Oncol. 2003; 22:A1029.
  115. Enzinger PC, Mayer RJ. . Colon cancer and other gastrointestinal malignancies. Cassel CK, Leipzig RM, Cohen HJ, Larson EB, Meier DE, eds. Geriatric Medicine an Evidence Based Approach. 2003; 417-440.
  116. Ryan DP, Clark JW, Kulke MH, Fuchs CS, Earle CC, Enzinger PC, Stuart K, Catarius KJ, Winkelmann J, Mayer RJ. A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. Cancer Invest. 2003; 21(4):505-11. PMID: 14533439.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  117. Kulke M, Bergsland E, Ryan DP, Clark JW, Enzinger PC, Michelini A, Kinsella K, Fogler W, Venook A, Fuchs C. . A phase II, open-label, safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc Annu Meet Am Soc Clin Oncol. 2003; 22:A958.
  118. Enzinger PC. Review of locally advanced esophageal carcinoma: at the crossroads of evidence-based medicine and patient care. Clin Adv Hematol Oncol. 2003; 1(5):292.
  119. Enzinger PC, Fuchs CS. . Clinical studies in gastric cancer. Ca Invest. 2002; 20:A20.
  120. Enzinger PC, Mayer RJ. . The Roswell Park Regimen: Weekly 5-FU and High-Dose Leucovorin for Colon Cancer. Colorectal Cancer: A Clinical Guide to Therapy. 2002; 441-51.
  121. Ryan DP, Eder JP, Winkelman T, Lynch T, Supko J, Appleman LJ, Fidias P, Enzinger P, Zhu A, Kinchla N, Esseltine D, Baldwin A, Elliot P, Adams J, Kauffman M, Schenkein D, Cusack J. . Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors. Proc Annu Meet Am Soc Clin Oncol. 2002; 21:A379.
  122. Fuchs CS, Lynch TJ, Earle CC, Enzinger PC, Kulke MH, Vincintore M, Seiden MV, Ryan DP, Mayer RJ, Clark JW. . Phase I Trial of Taxotere, Cisplatin, and CPT-11 (TPC) in Advanced Solid Tumor Malignancies. Proc Annu Meet Am Soc Clin Oncol. 2001; 20:A2087.
  123. Enzinger PC, Ilson DH. Irinotecan in esophageal cancer. Oncology (Williston Park). 2000 Dec; 14(12 Suppl 14):26-30. PMID: 11200145.
    Citations: 1     Fields:    Translation:Humans
  124. Kulke MH, Fuchs CS, Stuart K, Ryan DP, Enzinger PC, Vincitore M, Berg D, Clark JW, Mayer RJ. . Phase II Study of Docetaxel in Patients with Metastatic Carcinoid Tumors. Proc Annu Meet Am Soc Clin Oncol. 2000; 19:A1233.
  125. Enzinger PC, Ilson DH. Irinotecan in Esophageal Cancer. Oncology 2000. 2000; 14(14):S26-30.
  126. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G, Kelsen DP. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999 Oct; 17(10):3270-5. PMID: 10506629.
    Citations: 56     Fields:    Translation:HumansCTClinical Trials
  127. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin Oncol. 1999 Oct; 26(5 Suppl 15):12-20. PMID: 10566606.
    Citations: 32     Fields:    Translation:Humans
  128. Enzinger PC, Ilson DH, Saltz LB, Martin LK, Kelsen DP. Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma. Cancer. 1999 Mar 15; 85(6):1213-7. PMID: 10189124.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  129. Enzinger P, Ilson D, Minsky B, O’Reilly E, Schwartz G, Bains M, Turnbull A, Heelan R, Lipton R, Ginsberg R, Kelsen D. . Phase I/II Neoadjuvant Concurrent 96-Hour Taxol, Cisplatin, and Radiation Therapy: Promising Toxicity Profile and Response in Localized Esophageal Cancer. Proc Annu Meet Am Soc Clin Oncol. 1999; 18:A1038.
  130. Ilson D, Enzinger P, Saltz L, O’Reilly E, Schwartz G, Sharma S, Gollub M, Huang Y, Gonzalez G, and D Kelsen. . Phase II Trial of Weekly Irinotecan + Cisplatin in Advanced Gastric Cancer. Proc Annu Meet Am Soc Clin Oncol. 1999; 18:A994.
  131. Enzinger PC, Ilson DH, Saltz LB, O'Reilly EM, Kelsen DP. Irinotecan and cisplatin in upper gastrointestinal malignancies. Oncology (Williston Park). 1998 Aug; 12(8 Suppl 6):110-3. PMID: 9726102.
    Citations: 4     Fields:    Translation:HumansAnimals
  132. Enzinger PC, Ilson DH, Saltz LB, O’Reilly EM, Kelsen DP. . Irinotecan and cisplatin in upper gastrointestinal malignancies. Oncology. 1998; 8(6):110-113.
  133. Enzinger PC, Ilson DH. . Combined Modality Therapy for Locally Advanced Esophageal Carcinoma. Journal of Oncology Index and Reviews. 1998; 2(3):3-6.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Enzinger's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (242)
Explore
_
Co-Authors (83)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.